MedDataX Logo

PET-CT Based Radiotherapy in Esophageal Cancer Patients

NCT ID: NCT01156831

Last Updated: 2014-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

115 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-11-30

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Neoplasms

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Esophageal cancer PET-CT planning

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus
* Local curable disease able to undergo Chemoradiotherapy.

Exclusion Criteria

* Metastasized disease.
* Previous or concurrent malignancies.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht Radiation Oncology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guido Lammering, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Radiation Oncology, Maastro Clinic

Meindert Sosef, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Atrium Hospital Heerlen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Atrium Hospital

Heerlen, , Netherlands

Site Status

University Medical Center

Maastricht, , Netherlands

Site Status

St. Laurentius Hospital

Roermond, , Netherlands

Site Status

Maasland Hospital

Sittard, , Netherlands

Site Status

St. Jansgasthuis

Weert, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09-18-12/08

Identifier Type: -

Identifier Source: org_study_id